GlassScriptPhysician profile
Jamie V Ross
NPI 1831239284
$3,567.07
in general payments reported to CMS, 2019-2025
24 companies · $863 in 2025
The $863 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $513 · 2022: $252 · 2023: $759 · 2024: $1,180 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,801.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $556.86 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $462.07 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $436.17 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $421.74 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $324.29 | 2021-2025 | |
| Shield Therapeutics INC | $266.72 | 2023-2025 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.88 | 2021-2025 | Jardiance |
| Abbvie INC. | $137.04 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $134.12 | 2024-2025 | |
| Amgen INC. | $79.59 | 2021-2023 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $75.82 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.66 | 2022-2024 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $65.56 | 2021 | |
| Exact Sciences Corporation | $49.51 | 2023-2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $43.82 | 2024-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $41.46 | 2024-2025 | Inspire |
| Amarin Pharma, INC. | $37.55 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.87 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $19.06 | 2023 | Linzess |
| Dexcom, INC. | $18.98 | 2023 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $17.12 | 2022 | |
| Insulet Corporation | $14.10 | 2024 | Omnipod |
| Idorsia Pharmaceuticals US INC | $12.90 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.